Slide 1: Acquisition of Medivation
Acquisition of Medivation August 22, 2016
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Our discussions during this conference call will include forward-looking statements about, among other things, Pfizer, Medivation and Pfizer’s planned acquisition of Medivation, including its potential benefits, anticipated earnings accre
Slide 3: Important Information About the Tender Offer
Important Information About the Tender Offer The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities, nor is it a substitute for the tender off
Slide 4: Aligns with Pfizer Core Priorities and Key Focus Areas for Pfizer Oncology
Aligns with Pfizer Core Priorities and Key Focus Areas for Pfizer Oncology Pfizer’s Strategic Priorities Pfizer Oncology Business Priorities Deploy capital to efficiently create Strengthen category leadership in meaningful shareholder value oncology with flagship products Bias towards deal
Slide 5: Medivation's Compelling Value Proposition
Medivation’s Compelling Value Proposition Unique Blockbuster Oncology Opportunity Best in Class Prostate Cancer Treatment Commercial-stage company with strong growth outlook for marketed asset Leading franchise in metastatic castration-resistant $1.9bn in 2015 sales* prostate cancer (CRPC), an area
Slide 6: Transaction Overview
Transaction Overview $81.50 per share, net to the seller in cash, without interest, subject to any Purchase required withholding of taxes; 100% cash consideration Price Enterprise value of approximately $14 Billion Expected to be immediately accretive to adjusted diluted EPS* upon closing; Fin
Slide 7: Combination Complementary with Pfizer's Broad Portfolio of Cancer Therapies
Combination Complementary with Pfizer’s Broad Portfolio of Cancer Therapies Solid Tumors Hematology Immuno-Oncology Avelumab (anti-PD-L1) 4-1BB Anti-PD-1 OX40 Pidilizumab Inotuzumab Vaccines CAR-T Talazoparib Combined company will increase Pfizer’s scale and ability to bring breakthrough medicines t
Slide 8: With Ibrance and Xtandi, Pfizer Will Have Leading Treatments for the Most Common Cancers
With Ibrance and Xtandi, Pfizer Will Have Leading Treatments for the Most Common Cancers in Both Women and Men 600,000 550,000 500,000 Incidence 450,000 2016 Projected Incidence in G71 Breast Cancer ~585,000 400,000 Prostate Cancer ~580,000 350,000 2000 2002 2004 2006 2008 2010 2012 2014 2016 Prosta
Slide 9: With Ibrance and Xtandi, Pfizer Projected to Have Two of the Top Ten Oncology Products in 2021
With Ibrance and Xtandi, Pfizer Projected to Have Two of the Top Ten Leading Oncology Products in 2021 Source: EvaluatePharma, 2021 projected end-user sales. 9
Slide 10: Xtandi Development Plan in Prostate
Xtandi Development Plan in Prostate Xtandi’s development program began in later-line prostate cancer and is generating data earlier in the treatment paradigm, potentially helping more men live longer with extended time on effective therapy Current label in metastatic CRPC with a significant overall
Slide 11: Attractive Pipeline Assets
Attractive Pipeline Assets Talazoparib Pidilizumab PARP Inhibitor Immuno-oncology Agent Differentiated Mechanism of Action Activity demonstrated in hematologic malignancies and DIPG (diffuse Phase 3 study in BRCA-mutated breast intrinsic pontine glioma) cancer results expected in 2017 Curren
Slide 12: Key Takeaways
Key Takeaways Consistent with Pfizer strategy to add attractive assets with near-term revenue Xtandi is a blockbuster oncology asset in metastatic CRPC, an area of high unmet need Leading prostate franchise complements Ibrance and Pfizer’s immuno- oncology portfolio and adds commercial scale